Obesity Drugs Do Far More Than Shrink Waistlines, Major Review Finds

Obesity is no longer viewed simply as excess weight but as a gateway disease that triggers cascading metabolic, cardiovascular, neuropsychiatric, reproductive, and mechanical disorders. This framing, now reflected in clinical guidelines, has accelerated the use of pharmacotherapy as disease-modifying treatment rather than a last resort.

Researchers at Erasmus MC University Medical Center Rotterdam conducted a sweeping narrative review of randomized controlled trials and high-quality meta-analyses examining both approved and late-stage investigational obesity medications. The drug roster spans older agents such as phentermine-topiramate and naltrexone-bupropion, established GLP-1 receptor agonists like liraglutide and oral and subcutaneous semaglutide, and cutting-edge multiagonist therapies including tirzepatide, survodutide, mazdutide, retatrutide, cagrilintide-semaglutide, and amycretin.

Across a remarkably broad spectrum of comorbidities — type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, heart failure, cardiovascular disease, obstructive sleep apnea, polycystic ovary syndrome, osteoarthritis, muscle mass preservation, depression, quality of life, food cravings, binge-eating and substance use disorders, and neurodegenerative diseases — GLP-1-based and multiagonist therapies consistently demonstrated beneficial effects. While weight loss clearly mediates many of these gains, accumulating evidence points to direct, weight-loss-independent mechanisms, particularly pronounced with GLP-1 receptor agonist-based therapies.

These pleiotropic effects have significant implications for clinical practice: physicians may increasingly select specific obesity medications based on a patient's particular constellation of comorbidities rather than weight loss potential alone, enabling truly personalized obesity management.

Key caveats include the review's reliance on abstract-level evidence only for this summary, the heterogeneity of included trials, potential conflicts of interest among authors with pharmaceutical ties, and the evolving evidence base for the newest investigational agents, which may lack long-term safety data.